Tilray Inc (NASDAQ:TLRY) – Research analysts at Piper Jaffray Companies cut their FY2019 EPS estimates for shares of Tilray in a note issued to investors on Tuesday, November 12th. Piper Jaffray Companies analyst M. Lavery now anticipates that the company will post earnings of ($1.48) per share for the year, down from their prior forecast of ($1.11). Piper Jaffray Companies has a “Overweight” rating and a $31.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Tilray’s Q4 2019 earnings at ($0.39) EPS, Q1 2020 earnings at ($0.33) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.26) EPS, Q4 2020 earnings at ($0.20) EPS, FY2020 earnings at ($1.07) EPS, Q1 2021 earnings at ($0.20) EPS, Q2 2021 earnings at ($0.17) EPS, Q3 2021 earnings at ($0.16) EPS and FY2021 earnings at ($0.67) EPS.
Other equities analysts have also issued reports about the company. MKM Partners decreased their price objective on Tilray from $34.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday. Jefferies Financial Group set a $25.00 price objective on Tilray and gave the stock a “hold” rating in a report on Friday, October 25th. Northland Securities reissued a “hold” rating on shares of Tilray in a report on Wednesday, August 14th. Zacks Investment Research raised Tilray from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Finally, Benchmark reissued a “buy” rating and issued a $40.00 price objective (down from $80.00) on shares of Tilray in a report on Wednesday. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $43.13.
Tilray (NASDAQ:TLRY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.05). Tilray had a negative return on equity of 43.60% and a negative net margin of 97.39%. The business had revenue of $51.10 million during the quarter, compared to the consensus estimate of $49.57 million. During the same period last year, the company earned ($0.08) earnings per share. The business’s quarterly revenue was up 411.0% compared to the same quarter last year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Tilray during the 3rd quarter valued at $3,556,000. First Mercantile Trust Co. boosted its stake in Tilray by 9.9% during the 3rd quarter. First Mercantile Trust Co. now owns 8,900 shares of the company’s stock valued at $220,000 after purchasing an additional 800 shares in the last quarter. Sigma Planning Corp boosted its stake in Tilray by 1,837.5% during the 3rd quarter. Sigma Planning Corp now owns 9,834 shares of the company’s stock valued at $243,000 after purchasing an additional 10,400 shares in the last quarter. California Public Employees Retirement System boosted its stake in Tilray by 27.3% during the 3rd quarter. California Public Employees Retirement System now owns 8,700 shares of the company’s stock valued at $215,000 after purchasing an additional 1,864 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in Tilray by 9.6% during the 3rd quarter. Commonwealth Equity Services LLC now owns 29,148 shares of the company’s stock valued at $721,000 after purchasing an additional 2,549 shares in the last quarter. 7.76% of the stock is owned by hedge funds and other institutional investors.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Article: Depreciation
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.